Seniors' risk of dementia is more than double what was previously thought. The risk of developing dementia after age 55 is more than 42% among Americans, researchers reported in a study published Monday in the journal Nature Medicine.

New research suggests that the risk for developing dementia is significantly higher than previously estimated, and the burden on the United States population will grow substantially over the next few decades.

The risk of developing dementia in the United States is much higher than previously estimated, according to a new study published in the journal "Nature Medicine" on Monday.

Fact checked by Nick Blackmer Dementia cases in the United States are expected to double by 2060, increasing from over 500,000 new cases annually in 2020 to around 1 million new cases each year by 2060,

U.S. dementia cases are projected to double by 2060, with a new study predicting a rise in the burden of the disease nationally.

New cases of dementia in the United States are projected to double in the next three decades, a new study suggests. The study, published this week in the journal Nature Medicine, looked at more than 15,000 people and estimated the lifetime risk of dementia ...

By 2060, new dementia cases per year could double to one million because of the growing population of older Americans, a study predicts.

"Our study results forecast a dramatic rise in the burden from dementia in the United States over the coming decades, with one in two Americans expected to experience cognitive difficulties after age 55," said study senior investigator and epidemiologist ...

Vaccines, antibiotics, antiviral medications and anti-inflammatory drugs are all associated with a reduced risk of dementia, researchers reported in a study published Tuesday in the journal Alzheimer's and Dementia: Translational Research & Clinical Interventions .

"Our study results forecast a dramatic rise in the burden from dementia in the United States over the coming decades, with one in two Americans expected to experience cognitive difficulties after ...

"Our study results forecast a dramatic rise in the burden from dementia in the United States over the coming decades, with one in two Americans expected to experience cognitive difficulties after ...

As part of the regulatory action, memantine/donepezil extended-release capsules have been granted a 180-day exclusivity in patients with Alzheimer disease, with Everolimus receiving approval for tuberous sclerosis complex.